Zingo Information

Peripheral venous access procedures are among the most frequently reported painful events in hospitalized children.(2) The American Pain Society and the American Academy of Pediatrics, among other organizations, have developed recommendations that emphasize the importance of minimizing procedural pain in children whenever possible.(7) However, despite the existence of these recommendations, children undergoing these procedures remain largely under- treated.(8) Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, 0.5 mg is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine powder to provide topical, local analgesia to reduce the pain associated with peripheral IV insertions or blood draws, approved for use in children aged three to 18. Zingo's rapid onset of action allows intravenous line placement or venipuncture to begin one to three minutes after administration. In clinical trials, the most common adverse events with Zingo were redness, red dots and swelling. For full Zingo prescribing information, go to http://www.zingo.com.